Staar Surgical Company (STAA)
Deciphering Staar Surgical (STAA) International Revenue Trends
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STAAR Surgical Q2 Earnings Call Highlights
STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago.
Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?
Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript
STAAR Surgical Q1 Earnings Call Highlights
STAAR Surgical NASDAQ: STAA said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls following a difficult 2025.
Compared to Estimates, Staar Surgical (STAA) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.52 per share a year ago.
Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
